期刊
DIAGNOSTICS
卷 12, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics12010124
关键词
cancer; immunotherapy; biomarker; microenvironment; microbiome; flow cytometry; cytokine
Immune checkpoint inhibitors have changed the way cancer is treated but their effectiveness is limited and they can cause autoimmune side effects. Existing biomarkers are not sensitive or specific. This review discusses emerging tumor and immune tissue biomarkers and the impact of the gut microbiome on treatment outcomes.
Immune checkpoint inhibitors are monoclonal antibodies that are used to treat over one in three cancer patients. While they have changed the natural history of disease, prolonging life and preserving quality of life, they are highly active in less than 40% of patients, even in the most responsive malignancies such as melanoma, and cause significant autoimmune side effects. Licenced biomarkers include tumour Programmed Death Ligand 1 expression by immunohistochemistry, microsatellite instability, and tumour mutational burden, none of which are particularly sensitive or specific. Emerging tumour and immune tissue biomarkers such as novel immunohistochemistry scores, tumour, stromal and immune cell gene expression profiling, and liquid biomarkers such as systemic inflammatory markers, kynurenine/tryptophan ratio, circulating immune cells, cytokines and DNA are discussed in this review. We also examine the influence of the faecal microbiome on treatment outcome and its use as a biomarker of response and toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据